Risperidone
- Generic Name
- Risperidone
- Brand Names
- Perseris, Risperdal, Rykindo, Uzedy, Okedi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O2
- CAS Number
- 106266-06-2
- Unique Ingredient Identifier
- L6UH7ZF8HC
- Background
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...
- Indication
Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...
- Associated Conditions
- Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
- Associated Therapies
- -
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial
Teva presented positive data on TEV-'749, a subcutaneous olanzapine extended-release injection, at Psych Congress 2024, showing significant improvement in social functioning and quality of life in schizophrenia patients with no Post-Injection Delirium/Sedation Syndrome (PDSS) events. Real-world analyses of UZEDY (risperidone) subcutaneous long-acting injectable revealed high adherence rates among adults with treatment barriers.
Why I'm wary of the new schizophrenia miracle drug
The FDA approved Cobenfy, a new antipsychotic with fewer side effects, but trust issues persist due to historical psychiatric abuses and pharmaceutical misconduct. Patients with schizophrenia feel unheard and mistrustful, highlighting the need for their inclusion in drug development and marketing.
Uzedy: Reducing the Risk of Relapse in Patients With Schizophrenia
New data on Uzedy, an extended-release risperidone for schizophrenia, presented at ECNP Congress, shows significant relapse reduction vs. placebo. Pharmacokinetic simulations indicate comparable properties when switching from once-monthly RBP-7000 to Uzedy.
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies
Schizophrenia clinical trial pipeline features 55+ companies and 60+ drugs, with key players like Sumitomo Pharma America, Boehringer Ingelheim, and Reviva Pharmaceuticals advancing novel therapies. Recent milestones include Reviva's Phase III RECOVER trial data, Luye Pharma Group's IND approval for LY03020, and Teva's positive SOLARIS trial results. DelveInsight's report provides comprehensive global coverage and insights into the schizophrenia pipeline.
How One Biotech Is Using FDA 505(b)(2) To Get Drugs To Patients Quicker And Cheaper
Terran Biosciences, led by CEO Sam Clark, is leveraging the FDA's 505(b)(2) pathway to expedite the development of TerXT, a new treatment for schizophrenia. By referencing data from Bristol Myers Squibb's Cobenfy, Terran aims to create a once-daily oral dose and a long-acting injectable version of TerXT, addressing Cobenfy's limitations. This approach, which includes the use of prodrugs, aims to provide more affordable and accessible treatment options for patients.
Medincell's Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal
Teva presented positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult schizophrenia patients at ECNP 2024. The three doses align with oral olanzapine doses, simplifying physician transitions, and no new safety signals or PDSS were observed.
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed ...
Teva presented data on switching patients to UZEDY from Perseris at ECNP 2024, highlighting comparable pharmacokinetic profiles and patient-reported reasons for accepting long-acting injectable treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath